JBJoseph A. Beavo

Joseph A. Beavo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph A. Beavo has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Masami Shimizu-Albergine

    Department of Pharmacology, School of Medicine, University of Washington, USA

    6 shared publications
  • Sergei D. Rybalkin

    Department of Pharmacology, University of Washington, Seattle, WA 98195-7280; and

    5 shared publications
  • Enrico Patrucco

    Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino 10126, Italy

    4 shared publications
  • Andrew T. Bender

    Department of Pharmacology, University of Washington Medical School, Seattle, WA 98195; and

    3 shared publications
  • Franz Hofmann

    Institut für Pharmakologie und Toxikologie, Technische Universität München, D-80802 Munich, Germany

    3 shared publications
  • Sergio E. Martinez

    Department of Pharmacology, University of Washington, Seattle, Washington 98195, USA

    3 shared publications

Latest Publications

  • Open Access

    Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells

    by Michael-Claude G. Beltejar, Ho-Tak Lau, Martin G. Golkowski, Shao-En Ong, Joseph A. Beavo

    Significance: We have coupled mass spectrometry-based phosphoproteomic analyses with treatment using various selective PDE inhibitors to characterize the PDE-regulated phosphoproteome of CD3/CD28-stimulated Jurkat cells. Predictive algorithms were used to identify likely upstream regulatory kinases, metabolic pathways, and biological processes that can be regulated by different PDEs. Here we compare the phosphoproteomes of different functional compartments subserved by combinations of individual PDE isozymes in a T-cell model. We observed unique phosphoproteomes associated with specific combinations of PDEs. These data allow one to prioritize future experiments to understand further how these pathways are regulated by specific PDEs. The results also have substantial implications for the design and use of selective PDE inhibitors in clinical practice.


  • Studying mechanisms of cAMP and cyclic nucleotide phosphodiesterase signaling in Leydig cell function with phosphoproteomics

    by Martin Golkowski, Masami Shimizu-Albergine, Hyong Won Suh, Joseph A. Beavo, Shao-En Ong


  • Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis

    by Enrico Patrucco, Katrin Domes, Mauro Sbroggió, Anne Blaich, Jens Schlossmann, Matthias Desch, Sergei D. Rybalkin, Joseph A. Beavo, Robert Lukowski, Franz Hofmann

    Conflicting results have been reported for the roles of cGMP and cGMP-dependent protein kinase I (cGKI) in various pathological conditions leading to cardiac hypertrophy and fibrosis. A cardioprotective effect of cGMP/cGKI has been reported in whole animals and isolated cardiomyocytes, but recent evidence from a mouse model expressing cGKIβ only in smooth muscle (βRM) but not in cardiomyocytes, endothelial cells, or fibroblasts has forced a reevaluation of the requirement for cGKI activity in the cardiomyocyte antihypertrophic effects of cGMP. In particular, βRM mice developed the same hypertrophy as WT controls when subjected to thoracic aortic constriction or isoproterenol infusion. Here, we challenged βRM and WT (Ctr) littermate control mice with angiotensin II (AII) infusion (7 d; 2 mg⋅kg−1⋅d−1) to induce hypertrophy. Both genotypes developed cardiac hypertrophy, which was more pronounced in Ctr animals. Cardiomyocyte size and interstitial fibrosis were increased equally in both genotypes. Addition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking water had a small effect in reducing myocyte hypertrophy in WT mice and no effect in βRM mice. However, sildenafil substantially blocked the increase in collagen I, fibronectin 1, TGFβ, and CTGF mRNA in Ctr but not in βRM hearts. These data indicate that, for the initial phase of AII-induced cardiac hypertrophy, lack of cardiomyocyte cGKI activity does not worsen hypertrophic growth. However, expression of cGKI in one or more cell types other than smooth muscle is necessary to allow the antifibrotic effect of sildenafil.


  • Open Access

    Phosphodiesterase-8A binds to and regulates Raf-1 kinase

    by Kim M. Brown, Jon P. Day, Elaine Huston, Bastian Zimmermann, Kornelia Hampel, Frank Christian, David Romano, Selim Terhzaz, Louisa C. Y. Lee, Miranda J. Willis, et al.

    V-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1) is a key activator of the ERK pathway and is a target for cross-regulation of this pathway by the cAMP signaling system. The cAMP-activated protein kinase, PKA, inhibits Raf-1 by phosphorylation on S259. Here, we show that the cAMP-degrading phosphodiesterase-8A (PDE8A) associates with Raf-1 to protect it from inhibitory phosphorylation by PKA, thereby enhancing Raf-1’s ability to stimulate ERK signaling. PDE8A binds to Raf-1 with high (picomolar) affinity. Mapping of the interaction domain on PDE8A using peptide array technology identified amino acids 454–465 as the main binding site, which could be disrupted by mutation. A cell-permeable peptide corresponding to this region disrupted the PDE8A/Raf-1 interaction in cells, thereby reducing ERK activation and the cellular response to EGF. Overexpression of a catalytically inactive PDE8A in cells displayed a dominant negative phenotype on ERK activation. These effects were recapitulated at the organism level in genetically modified (PDE8A−/−) mice. Similarly, PDE8 deletion in Drosophila melanogaster reduced basal ERK activation and sensitized flies to stress-induced death. We propose that PDE8A is a physiological regulator of Raf-1 signaling in some cells. Significance The ERK pathway is a ubiquitous mechanism for transducing a variety of extracellular signals into intracellular events. It also is misregulated in a number of different disease states including several cancers. The ERK pathway crosstalks with other signaling cascades, including the cAMP system. In this paper, we show that a key component of the ERK pathway, Raf-1 kinase, can associate with a specific cyclic nucleotide phosphodiesterase, phosphodiesterase 8A (PDE8A), to modulate the activity of the kinase. We report that the interaction between Raf-1 and PDE8A underpins functional consequences of ERK signaling in several different model systems.


  • cAMP-Specific Phosphodiesterases 8A and 8B, Essential Regulators of Leydig Cell Steroidogenesis

    by Masami Shimizu-Albergine, Li-Chun Lisa Tsai, Enrico Patrucco, Joseph A. Beavo

    Phosphodiesterase (PDE) 8A and PDE8B are high-affinity, cAMP-specific phosphodiesterases that are highly expressed in Leydig cells. PDE8A is largely associated with mitochondria, whereas PDE8B is broadly distributed in the cytosol. We used a new, PDE8-selective inhibitor, PF-04957325, and genetically ablated PDE8A(−/−), PDE8B(−/−) and PDE8A(−/−)/B(−/−) mice to determine roles for these PDEs in the regulation of testosterone production. PF-04957325 treatment of WT Leydig cells or MA10 cells increased steroid production but had no effect in PDE8A (−/−)/B(−/−) double-knockout cells, confirming the selectivity of the drug. Moreover, under basal conditions, cotreatment with PF-04957325 plus rolipram, a PDE4-selective inhibitor, synergistically potentiated steroid production. These results suggest that the pool(s) of cAMP regulating androgen production are controlled by PDE8s working in conjunction with PDE4. Likewise, PDE8A (−/−)/B(−/−) cells had higher testosterone production than cells from either PDE8A(−/−) or PDE8B(−/−) mice, suggesting that both PDE8s work in concert to regulate steroid production. We further demonstrate that combined inhibition of PDE8s and PDE4 greatly increased PKA activity including phosphorylation of cholesterol-ester hydrolase (CEH)/hormone-sensitive lipase (HSL). CEH/HSL phosphorylation also was increased in PDE8A(−/−)/B(−/−) cells compared with WT cells. Finally, combined inhibition of PDE8s and PDE4 increased the expression of steroidogenic acute regulatory (StAR) protein. Together these findings suggest that both PDE8A and PDE8B play essential roles to maintain low cAMP levels, thereby suppressing resting steroidogenesis by keeping CEH/HSL inactive and StAR protein expression low. They also suggest that in order for PDE inhibitor therapy to be an effective stimulator of steroidogenesis, both PDE8 isozymes and PDE4 need to be simultaneously targeted.


  • Open Access

    Molecular targets for PDE inhibitor-mediated improvement of cardiac dysfunction in the mdx mouse?

    by Candace M Adamo, Dao-Fu Dai, Justin M Percival, Elina Minami, Monte S Willis, Enrico Patrucco, Sergei D Rybalkin, Stanley C Froehner, Joseph A Beavo

  • Regulation of Endothelial Barrier Function by Cyclic Nucleotides: The Role of Phosphodiesterases

    by James Surapisitchat, Joseph A. Beavo

    The endothelium plays an important role in maintaining normal vascular function. Endothelial barrier dysfunction leading to increased permeability and vascular leakage is associated with several pathological conditions such as edema and sepsis. Thus, the development of drugs that improve endothelial barrier function is an active area of research. In this chapter, the current knowledge concerning the signaling pathways regulating endothelial barrier function is discussed with a focus on cyclic nucleotide second messengers (cAMP and cGMP) and cyclic nucleotide phosphodiesterases (PDEs). Both cAMP and cGMP have been shown to have differential effects on endothelial permeability in part due to the various effector molecules, crosstalk, and compartmentalization of cyclic nucleotide signaling. PDEs, by controlling the amplitude, duration, and localization of cyclic nucleotides, have been shown to play a critical role in regulating endothelial barrier function. Thus, PDEs are attractive drug targets for the treatment of disease states involving endothelial barrier dysfunction.


  • Open Access

    The High-Affinity cAMP-Specific Phosphodiesterase 8B Controls Steroidogenesis in the Mouse Adrenal Gland

    by Li-Chun Lisa Tsai, Masami Shimizu-Albergine, Joseph A. Beavo

    The functions of the phosphodiesterase 8B (PDE8) family of phosphodiesterases have been largely unexplored because of the unavailability of selective pharmacological inhibitors. Here, we report a novel function of PDE8B as a major regulator of adrenal steroidogenesis using a genetically ablated PDE8B mouse model as well as cell lines treated with either a new PDE8-selective inhibitor or a short hairpin RNA (shRNA) construct against PDE8B. We demonstrate that PDE8B is highly enriched in mouse adrenal fasciculata cells, and show that PDE8B knockout mice have elevated urinary corticosterone as a result of adrenal hypersensitivity toward adrenocorticotropin. Likewise, ablation of PDE8B mRNA transcripts by an shRNA construct potentiates steroidogenesis in the commonly used Y-1 adrenal cell line. We also observed that the PDE8-selective inhibitor (PF-04957325) potentiates adrenocorticotropin stimulation of steroidogenesis by increasing cAMP-dependent protein kinase activity in both primary isolated adrenocortical cells and Y-1 cells. It is noteworthy that PDE8s have their greatest control under low adrenocorticotropin-stimulated conditions, whereas other higher Km PDE(s) modulate steroidogenesis more effectively when cells are fully stimulated. Finally, both genetic ablation of PDE8B and long-term pharmacological inhibition of PDE8s cause increased expression of steroidogenic enzymes. We conclude that PDE8B is a major regulator of one or more pools of cAMP that promote steroidogenesis via both short- and long-term mechanisms. These findings further suggest PDE8B as a potential therapeutic target for the treatment of several different adrenal diseases.


  • Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy

    by Candace M. Adamo, Dao-Fu Dai, Justin M. Percival, Elina Minami, Monte S. Willis, Enrico Patrucco, Stanley C. Froehner, Joseph A. Beavo

    Duchenne muscular dystrophy (DMD) is a progressive and fatal genetic disorder of muscle degeneration. Patients with DMD lack expression of the protein dystrophin as a result of mutations in the X-linked dystrophin gene. The loss of dystrophin leads to severe skeletal muscle pathologies as well as cardiomyopathy, which manifests as congestive heart failure and arrhythmias. Like humans, dystrophin-deficient mice ( mdx mice) show cardiac dysfunction as evidenced by a decrease in diastolic function followed by systolic dysfunction later in life. We have investigated whether sildenafil citrate (Viagra), a phosphodiesterase 5 (PDE5) inhibitor, can be used to ameliorate the age-related cardiac dysfunction present in the mdx mice. By using echocardiography, we show that chronic sildenafil treatment reduces functional deficits in the cardiac performance of aged mdx mice, with no effect on normal cardiac function in WT controls. More importantly, when sildenafil treatment was started after cardiomyopathy had developed, the established symptoms were rapidly reversed within a few days. It is recognized that PDE5 inhibitors can have cardioprotective effects in other models of cardiac damage, but the present study reports a prevention and reversal of pathological cardiac dysfunction as measured by functional analysis in a mouse model of DMD. Overall, the data suggest that PDE5 inhibitors may be a useful treatment for the cardiomyopathy affecting patients with DMD at early and late stages of the disease.